← All organizations
Highest phase reached
Phase 4
First clinical trial
Feb 1, 2007Last known activity
Oct 2, 2025
Timeline
1930s
- Jan 1, 1936
Instituto Nacional de Enfermedades Respiratorias— Founded
Drugs by trial phase (19 distinct, 18 trials)
Phase 4 (3 own, 0 via acquisition)
Phase 3 (3 own, 0 via acquisition)
Phase 2 (4 own, 0 via acquisition)
Other trials (9 own, 0 via acquisition)
Indications
Studied for
- Acquired Immunodeficiency Syndrome
- Carcinoma, Non-Small-Cell Lung
- Coinfection
- Communicable Diseases
- Cystic Fibrosis
- Diabetes Mellitus
- Fibrosis
- HIV Infections
- Immune Reconstitution Inflammatory Syndrome
- Immunologic Deficiency Syndromes
- Infections
- Latent Tuberculosis
- Lung Neoplasms
- Pneumonia
- Radiation Pneumonitis
- Sarcoma
- Sarcoma, Kaposi
- Tuberculosis
- Tuberculosis, Pulmonary
Recent trials (30)
- NCT06959251Sponsor investigatorN/AOct 2, 2025
- NCT06959251Lead sponsorN/AOct 2, 2025
- NCT06531460OfficialN/AJul 25, 2024
- NCT05710783CollaboratorPhase 2/Phase 3Nov 9, 2022
- NCT05205746CollaboratorPhase 2Nov 23, 2021
- NCT04443673Reponsible party - principal investigatorN/AAug 20, 2020
- NCT04443673Lead sponsorN/AAug 20, 2020
- NCT04443673Overall official - principal investigatorN/AAug 20, 2020
- NCT04388410CollaboratorPhase 2/Phase 3Jun 1, 2020
- NCT04405310CollaboratorPhase 2May 20, 2020
- NCT04432194Reponsible party - principal investigatorN/AAug 30, 2019
- NCT04432194Lead sponsorN/AAug 30, 2019
- NCT03803787CollaboratorPhase 2Sep 1, 2018
- NCT03278483CollaboratorPhase 4Jul 10, 2017
- NCT03278483Overall official - principal investigatorPhase 4Jul 10, 2017
Details
- Founded
- Mexico City, MX Jan 1, 1936
- Last known activity
- Oct 2, 2025